tirzepatide mash nash phase 3 Incretin-based therapy for MASH: are two better than one? Tirzepatide Found Superior to Placebo – Nearly 62% achieve MASH resolution

This was seen in association with increased baseline and post-prandial intact GLP-1 concentrations, reduced post-prandial glucagon levels and sustained insulin levels, which in the presence of lower glucose levels resulted in an increase of insulinogenic index as a sign of stimulated beta-cell function, which provided a first insight into the mechanism of action of DPP-4 inhibition in type 2 diabetes (Figure 4)

Your physician designs your stack based on goals and labs

Pasqua, M

From your starting dose, titration follows the standard tirzepatide schedule: increase by 2.5 mg every four weeks as tolerated, up to 15 mg

The 2007 Pyo study documented the same pattern at the cellular level: concentrations above 10 M actually inhibited hair follicle growth

,